NCT06424301View on ClinicalTrials.gov

Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
RetinoblastomaRefractory
Interventions
DRUG

Targeting NUDT21 siRNA drugs

It is performed for intravitreal chemotherapy.

Trial Locations (1)

Unknown

RECRUITING

Fudan Eye & ENT Hospital, Shanghai

All Listed Sponsors
collaborator

The Eye Hospital of Wenzhou Medical University

OTHER

lead

Eye & ENT Hospital of Fudan University

OTHER